Antiphospholipid Antibodies and Fetal Growth Restriction
|ClinicalTrials.gov Identifier: NCT01538134|
Recruitment Status : Unknown
Verified January 2015 by Osvaldo A. Reyes T., Saint Thomas Hospital, Panama.
Recruitment status was: Not yet recruiting
First Posted : February 23, 2012
Last Update Posted : January 5, 2015
|Condition or disease|
|Fetal Growth Restriction Antiphospholipid Syndrome|
|Study Type :||Observational|
|Estimated Enrollment :||90 participants|
|Observational Model:||Case Control|
|Official Title:||Antiphospholipid Antibodies and Early Fetal Growth Restriction (<34 Weeks of Gestation). A Case Control Study.|
|Study Start Date :||June 2015|
|Estimated Primary Completion Date :||February 2016|
|Estimated Study Completion Date :||March 2016|
Patients with ultrasonographic diagnosis of fetal growth restriction.
Patients with normal pregnancies at term.
- Lupus anticoagulant [ Time Frame: 8 months ]Number of cases positive for Lupus Anticoagulant.
- Anticardiolipin antibodies [ Time Frame: 10 months ]Number of cases with high/medium levels of IgG/IgM of anticardiolipin antibodies.
- B2 Glycoprotein I [ Time Frame: 10 months ]Number of cases with levels of B2 Glycoprotein I > 99%
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01538134
|Saint Thomas Maternity Hospital|
|Principal Investigator:||Osvaldo Reyes, MD||Saint Thomas Hospital, Panama|